Metabolites from Unculturable Microorganisms Create Drug Discovery Opportunity
ALBUQUERQUE, NM – The University of New Mexico’s Center for Global Health recently entered into a collaborative relationship with Biosortia Pharmaceuticals of Dublin, OH, to explore new, biologically active, natural products for various infectious disease treatments.
UNM Center for Global Health Co-Directors, Douglas J. Perkins, Ph.D., and Ravi Durvasula, M.D. – along with researchers at the Paratransgenesis Laboratory and Laboratories of Tropical Diseases – will accelerate studies worldwide on parasitic, vector-borne, and viral diseases; HIV/AIDS; emerging infectious diseases; and more.
UNM’s Center for Global Health will investigate the isolation, characterization, and biological evaluation of natural products to combat infectious and tropical diseases. Biosortia Pharmaceuticals will provide compounds produced by microscopic organisms in the natural aquatic environment, including microalgae, bacteria, and fungi, and their secondary metabolites.
This unique research collaboration will investigate the distinctive chemistry for activity against specific disease targets. Biosortia will be responsible for commercializing any new compounds to various pharmaceutical companies for further development into new drugs.
“As the world becomes more interconnected, it is apparent that the major global health burdens facing our international community will require an integrated approach,” remarks Perkins. “Our work with Biosortia Pharmaceuticals gives us exponential power in exploring the determinants of infectious diseases throughout the world, as well as here in New Mexico.”
“We look to collaborate with academia's best researchers in our strategic therapy areas,” adds Biosortia's President and CEO, Kurt Dieck. “We are very excited to enter into this collaboration agreement with UNM and to be able to work with such innovative and respected research leaders as Drs. Perkins and Durvasula."
Contact: Luke Frank, 272-3322